Want to see KNSA full AI Analyst Report?
KNSA Stock Chart & Stats
$80.20
$1.29(2.05%)
At close: 4:00 PM EDT
$80.20
$1.29(2.05%)
Day’s Range― - ―
52-Week Range$35.06 - $82.94
Previous CloseN/A
Volume57.84K
Average Volume (3M)604.55K
Market Cap
$6.23B
Enterprise Value$4.82K
Total Cash (Recent Filing)$525.93M
Total Debt (Recent Filing)$8.90M
Price to Earnings (P/E)75.2
Beta0.42
Next Earnings
Nov 03, 2026EPS Estimate
0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.07
Shares Outstanding48,289,272
10 Day Avg. Volume454,973
30 Day Avg. Volume604,549
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)5.39
Price to Sales (P/S)4.52
P/FCF Ratio120.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$96.57Price Target Upside20.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)1.39
Revenue Forecast (FY)$993.64M
Bulls Say, Bears Say
Bulls Say
ARCALYST Commercial MomentumStrong revenue growth, expanding prescriber adoption and higher patient penetration indicate increasing product acceptance. These trends can support durable commercial expansion as Kiniksa improves awareness and reaches more eligible recurrent-pericarditis patients.
Strong Balance Sheet And Cash GenerationRobust free cash flow and minimal leverage give Kiniksa substantial flexibility to fund clinical development, commercialization and business development without relying heavily on external financing. Strong cash conversion also supports the quality of current earnings.
Pipeline ExpansionAdvancing KPL-387 into Phase III creates a potential second growth driver beyond ARCALYST and could broaden Kiniksa's immunology platform. Monthly dosing and favorable response metrics may support future patient convenience and commercial differentiation if efficacy is confirmed.
Bears Say
Historical Earnings And Cash Flow VolatilityAlthough current profitability is strong, prior losses and uneven cash conversion show that earnings quality has not been consistently stable. This history creates execution risk if commercialization costs rise, working capital shifts, or product growth moderates.
Reliance On ARCALYST And Market EducationDependence on one principal product concentrates commercial and regulatory exposure. Reaching the broader patient population also requires sustained physician and patient education, which may lengthen adoption timelines and require continued sales and marketing investment.
Clinical Durability And Dosing UncertaintyLimited longer-term follow-up makes it harder to assess durability and recurrence prevention for KPL-387. The lack of support for lower doses also reduces dosing flexibility, potentially affecting development options, trial outcomes and eventual commercial positioning.
Kiniksa Pharmaceuticals News
KNSA FAQ
What was Kiniksa Pharmaceuticals’s price range in the past 12 months?
Kiniksa Pharmaceuticals lowest stock price was $35.06 and its highest was $82.94 in the past 12 months.
What is Kiniksa Pharmaceuticals’s market cap?
Kiniksa Pharmaceuticals’s market cap is $6.23B.
When is Kiniksa Pharmaceuticals’s upcoming earnings report date?
Kiniksa Pharmaceuticals’s upcoming earnings report date is Nov 03, 2026 which is in 60 days.
How were Kiniksa Pharmaceuticals’s earnings last quarter?
Kiniksa Pharmaceuticals released its earnings results on Jul 28, 2026. The company reported $0.3 earnings per share for the quarter, beating the consensus estimate of $0.299 by $0.001.
Is Kiniksa Pharmaceuticals overvalued?
According to Wall Street analysts Kiniksa Pharmaceuticals’s price is currently Undervalued.
Does Kiniksa Pharmaceuticals pay dividends?
Kiniksa Pharmaceuticals does not currently pay dividends.
What is Kiniksa Pharmaceuticals’s EPS estimate?
Kiniksa Pharmaceuticals’s EPS estimate is 0.37.
How many shares outstanding does Kiniksa Pharmaceuticals have?
Kiniksa Pharmaceuticals has 48,289,272 shares outstanding.
What happened to Kiniksa Pharmaceuticals’s price movement after its last earnings report?
Kiniksa Pharmaceuticals reported an EPS of $0.3 in its last earnings report, beating expectations of $0.299. Following the earnings report the stock price went up 25.033%.
Which hedge fund is a major shareholder of Kiniksa Pharmaceuticals?
Currently, no hedge funds are holding shares in KNSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kiniksa Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$96.57 (20.41% Upside)
$96.57 (20.41% Upside)
Blogger Sentiment
Bullish
KNSA Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 63.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $299.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
126.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
35.54%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
KNSA Company Deck
KNSA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong commercial execution for ARCALYST with substantial quarter-over-quarter and year-over-year revenue gains, expanded prescriber adoption, improved collaboration profit, a robust cash position, and positive Phase II data supporting a monthly KPL-387 regimen and initiation of the pivotal Phase III trial. Challenges include rising operating expenses, limited disclosure on some clinical follow-up details, remaining underdiagnosis in the market that requires continued education, and uncertainty around gross-to-net trends and future commercial resource expansion. On balance, the positive commercial and clinical milestones materially outweigh the noted operational and disclosure limitations.View all KNSA earnings summariesKNSA Stock 12 Month Forecast
Average Price Target
$96.57
▲(20.41% Upside)
Technical Analysis
Corcept Therapeutics
―
SCYNEXIS
―
Liquidia Technologies
―
Biofrontera
―
Nasus Pharma Ltd.
―
Ownership Overview
6.93% Insiders
23.16% Mutual Funds
32.58% Other Institutional Investors
23.05% Public Companies and
Individual Investors